Get the Stockscreener App
12.07
1.77%
0.21
Maze Therapeutics Inc stock is traded at $12.07, with a volume of 75,192.
It is up +1.77% in the last 24 hours and down -11.64% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$11.86
Open:
$12.16
24h Volume:
75,192
Relative Volume:
0.38
Market Cap:
$563.67M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.26%
1M Performance:
-11.64%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.98
$12.44
1-Week Range:
$10.98
$13.47
52-Week Range:
$6.71
$16.09
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
11.62 | 563.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.84 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position - TipRanks
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones - GlobeNewswire
Maze Therapeutics Q1 Earnings: Dual Clinical Programs Progress as Cash Position Hits $294M - Stock Titan
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times
Maze Therapeutics CEO to Present Company Overview at 3rd Annual H.C. Wainwright BioConnect Investor Conference - Nasdaq
Maze Therapeutics Inc (MAZE)’s Day in Review: Closing at 9.25, Up by 5.23 - DWinneX
Maze Therapeutics (NASDAQ:MAZE) versus Vaxcyte (NASDAQ:PCVX) Financial Survey - Defense World
Maze Therapeutics (NASDAQ:MAZE) Shares Down 19.4% – Here’s What Happened - Defense World
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Guggenheim Reiterates Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - Defense World
Leerink Partnrs Has Bearish Forecast for MAZE Q1 Earnings - Defense World
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewswire
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year - TipRanks
Maze Therapeutics Turns Profitable: $52M Net Income as Clinical Trials Progress - Stock Titan
Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (NASDAQ:MAZE) - Seeking Alpha
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period To End on March 12th - Defense World
Leerink Partners Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.6%Still a Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs - Defense World
Maze Therapeutics (NASDAQ:MAZE) Upgraded at TD Cowen - Defense World
FY2024 Earnings Estimate for MAZE Issued By Leerink Partnrs - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co. - Defense World
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Guggenheim - Defense World
Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Maze Therapeutics initiated with a Buy at TD Cowen - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners - Defense World
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829 - TipRanks
Cowen initiates Maze Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Maze Therapeutics receives positive ratings following recent IPO - Investing.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Guggenheim sets $19 target on Maze Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target -February 25, 2025 at 06:43 am EST - Marketscreener.com
JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target -February 25, 2025 at 06:32 am EST - Marketscreener.com
Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics - TipRanks
Maze Therapeutics initiated with an Outperform at Leerink - TipRanks
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market - TipRanks
JPMorgan sets Maze Therapeutics stock to Overweight with $30 target By Investing.com - Investing.com Canada
This New Drug Mimics The Health Effects of Living at High Altitude - ScienceAlert
Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month LowShould You Sell? - MarketBeat
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.34%
7.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):